Last updated: March 5, 2025
Sponsor: University Children's Hospital Basel
Overall Status: Active - Recruiting
Phase
N/A
Condition
Leukemia
Female Hormonal Deficiencies/abnormalities
Hormone Deficiencies
Treatment
N/AClinical Study ID
NCT06861530
2024-00736
Ages < 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
diagnosed with ALL or LBL
treated for at least 21 sequential days with glucocorticoids between the 01.07.2024and the 30.06.2027 at the Childrens University Hospital of Basel or at the ChildrensHospital of Aarau
lnformed consent can be obtained from the patient's legal representatives (andthe patient if at least 14 years of age) within week 2 of treatment withglucocorticoids
Exclusion
Exclusion Criteria:
- Contraindication to the administration of intravenous synthetical ACTH (Synacthen®):extremely rare cases of known or suspected hypersensitivity to Synacthen®.
Study Design
Total Participants: 40
Study Start date:
August 13, 2024
Estimated Completion Date:
June 30, 2026
Connect with a study center
KSA
Aarau,
SwitzerlandActive - Recruiting
UKBB
Basel,
SwitzerlandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.